The C1orf159 Knockout Jurkat Polyclonal Cells product provides a heterogeneous population of CRISPR/Cas9-edited Jurkat cells with targeted disruption of the C1orf159 gene. This polyclonal knockout cell pool is generated by introducing Cas9 and a guide RNA complex into the host Jurkat cell line, leading to gene disruption across the population without clonal isolation. The resulting cell mixture retains the functional diversity of a polyclonal background, enabling robust loss-of-function studies while avoiding artifacts associated with single-cell cloning. As a ready-to-use reagent, it eliminates the need for in-house genome editing and streamlines downstream assays.
The Jurkat cell line is an immortalized human T lymphocyte line originally derived from the peripheral blood of a patient with acute T cell leukemia. Jurkat cells are widely used as a model for T cell receptor (TCR) signaling, adaptive immune responses, and cytokine production. They express key TCR components and downstream signaling molecules, and they can be activated to produce cytokines such as interleukin-2 upon appropriate stimulation. This well-characterized cellular background makes Jurkat cells a preferred system for investigating T cell biology, signal transduction, and cancer immunology.
The C1orf159 gene encodes a protein whose biological function remains largely uncharacterized. Emerging evidence suggests a potential role in the regulation of cell growth, and it has been implicated in tumorigenesis, with associations to colorectal, breast, and hepatocellular carcinomas. However, the upstream regulators, downstream targets, and interacting partners of C1orf159 are currently not established. Its mechanistic contributions to signaling networks are unknown, and it does not map to well-defined canonical pathways. Given this, the C1orf159 knockout Jurkat model serves as a clean genetic background to probe its function and to identify molecular interactors and pathway connections.
In the Jurkat T lymphocyte context, disruption of C1orf159 provides a platform to dissect its role in TCR-mediated signaling, adaptive immunity, and leukemogenesis. Because Jurkat cells are leukemic in origin, they inherently model aspects of transformed lymphocyte biology. This knockout system can be employed to assess how loss of C1orf159 affects cell proliferation, survival, and cytokine output under activating conditions. Moreover, it allows comparative studies across cancer types, given the gene??s association with multiple solid tumors, although direct implications in T-cell leukemia remain to be explored.
Typical experimental workflows include western blotting to confirm protein depletion, RT-qPCR to quantify target transcript levels, and RNA-seq for global transcriptome analysis. Functional assays such as cell proliferation and apoptosis measurements can evaluate the impact of C1orf159 disruption on cell fitness. This product is suitable for researchers aiming to map C1orf159-dependent signaling events, to discover downstream effectors, or to investigate its contribution to cancer cell biology in an immune-cell environment. For additional technical details and custom requests, please contact Ascent Research.
